Contrast Media/Contrast Agents Market By Product (Iodinated, Gadolinium & Barium), By Technique (X-ray, CT, MRI, Cath Lab & Ultrasound) & By Application (Radiology, Interventional Radiology & Interventional Cardiology) - Global Trends & Forecast to 2017 [※Contents Updated on 2-May-2014]

[Updated] 世界の造影剤(コントラスト剤)市場動向(~2017)

◆タイトル:Contrast Media/Contrast Agents Market By Product (Iodinated, Gadolinium & Barium), By Technique (X-ray, CT, MRI, Cath Lab & Ultrasound) & By Application (Radiology, Interventional Radiology & Interventional Cardiology) - Global Trends & Forecast to 2017 [※Contents Updated on 2-May-2014]
◆商品コード:Markets-MD1371
◆調査・発行会社:MarketsandMarkets
◆発行日:2013年1月
◆ページ数:286
◆レポート形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Multi User(~5名)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate licence (社内共有可) USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"[Updated] 世界の造影剤(コントラスト剤)市場動向(~2017)"について調査・分析し、イントロダクション、エグゼクティブサマリー、市場概観、投資機会、市場の動態、地域別分析、市場規模及び予測、競争状況、市場シェア分析、新製品発売、主要企業(ベンダー)分析等の情報をお届けいたします。

Contrast agents have evolved significantly over the past century, from barium and iodine-based agents that were used initially by medical practitioners and radiologists, to the more advanced agents like radiopharmaceuticals and gold nanoparticles that are currently in use. Sophisticated techniques such as targeted MRI imaging and gas microbubble technology in ultrasound will prove to be essential drivers in the widespread use of contrast agents in the future.

The global contrast media market is broadly segmented into barium-based, iodinated and gadolinium-based contrast media. These products are further categorized based on the medical procedure (X-ray, CT, MRI, ultrasound, and catheterization laboratory), route of administration (oral, injection, rectal, and urethral), medical indication (cardiovascular, respiratory, musculoskeletal, gastrointestinal, and neurology, nephrology and oncology) and finally application (radiology, interventional radiology and interventional cardiology). The global contrast media market is worth $6.2 billion in 2012, and estimated to grow at a CAGR of 6.8% to reach $8.6 billion by 2017.

The global contrast media market, though fairly mature at present (2012), still shows potential to grow over the next five years. It is propelled by the increasing demand for diagnostic imaging and image guided surgical procedures, technological advances in diagnostic imaging and the ever-increasing incidence rates of cancer and cardiac disorders. However, a few pivotal factors affecting the growth of this market are major economies of the world undergoing healthcare reforms, thereby affecting contrast media sales and the economic slowdown restricting the overall growth of this market.

The U.S. represents the largest contrast media market worldwide, followed by Europe and Japan. However, the economic slowdown has augmented opportunities for emerging markets like India and China to strengthen their position in the global arena. Advances in medical technology coupled with huge foreign investments from developed nations, allows these emerging markets to compete with global market leaders in this segment. Investment firms are increasingly focusing on expansion in developing markets of Asia, Latin America and Eastern Europe, since the U.S. is on the brink of embracing healthcare reforms and major economies in Europe are still recovering from huge financial deficits.

The global marketplace is highly competitive, with several small players specific to a particular geography challenging major ones. Owing to the recession and the emerging opportunities in developing countries, many small companies have similar product offerings at competitive prices. Some of the major players profiled in this report are GE Healthcare (U.K.), Bracco Diagnostic, Inc. (Italy), Bayer Healthcare Pharmaceuticals (Germany), Covidien (Ireland) and Guerbet Group (France).

The scope of the report spans the global contrast media market which comprises:

Global Contrast Media Market, by Product

Barium-based contrast media
Iodinated contrast media
Low-osmolar contrast media (LOCM)
High-osmolar contrast media (HOCM)
Gadolinium-based contrast media
Global Contrast Media Market, by Route of Administration

Oral
Injection
Intravenous (I.V.)
Intra-arterial (I.A.)
Rectal
Urethral
Global Contrast Media Market, by Medical Procedure

X-ray
Computed tomography (CT)
Magnetic resonance imaging (MRI)
Ultrasound
Catheterization laboratory (cath lab)
Global Contrast Media Market, by Indication

Cardiovascular disorders
Neurological disorders
Gastrointestinal disorders
Respiratory diseases
Musculoskeletal anomalies
Nephrological disorders
Oncology (tumor detection)
Global Contrast Media Market, by Application

Radiology
Interventional radiology
Interventional cardiology
Contrast Media Market, by Geography

North America
U.S.
Canada
Europe
United Kingdom (U.K.)
Germany
France
Italy
Spain
Scandinavian countries (Sweden, Denmark, Finland, and Norway)
Rest of Europe
Asia-Pacific (APAC)
Japan
China
India
Rest of Asia-Pacific
Rest of the world (RoW)
Latin America
Middle East & Africa
Russia
Each section of the report offers market data for the various market segments and geographies. It also provides in-depth information on market trends with respect to drivers, restraints, opportunities and technology trends.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 MARKET DYNAMICS
3.3.1 DRIVERS
3.3.1.1 INCREASING DEMAND FOR DIAGNOSTIC & IMAGE GUIDED PROCEDURES INFLUENCES CONTRAST MEDIA SALES
3.3.1.2 TECHNOLOGICAL ADVANCEMENTS TO SPUR THE CONTRAST MEDIA MARKET
3.3.1.3 INCREASING INCIDENCE & MORTALITY OF CANCER & CARDIAC DISEASES TO BOOST GROWTH OF CONTRAST MEDIA
3.3.1.4 GROWTH OF MEDICAL IMAGING TECHNOLOGY IN EMERGING MARKETS
3.3.2 RESTRAINTS
3.3.2.1 MAJOR ECONOMIES UNDERGOING HEALTHCARE REFORMS TO AFFECT THE SALES ON CONTRAST MEDIA
3.3.2.2 ECONOMIC SLOWDOWN TO INHIBIT GROWTH
3.3.3 OPPORTUNITIES
3.3.3.1 GROWING INVESTMENT POTENTIAL IN IMMATURE EMERGING MARKETS
3.3.3.2 ADVENT OF NOVEL CONTRAST AGENTS COMBINING PROPERTIES OF CONTRAST MEDIA & RADIOPHARMACEUTICALS
3.3.4 BURNING ISSUE – TOXICITY
3.3.4.1 NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
3.3.4.2 CONTRAST-INDUCED NEPHROTOXICITY (CIN)
3.3.5 TECHNOLOGY TRENDS
3.3.5.1 N1177 – A REVOLUTIONARY MACROPHAGE LABELING AGENT
3.3.5.2 SPAGO PIX – ACCURATE VISUALIZATION OF TUMORS WITH MRI
3.3.5.3 CMC-001 – FOCUSED ON LIVER MRI
3.4 MARKET SHARE ANALYSIS

4 BY PRODUCT
4.1 INTRODUCTION
4.2 BARIUM-BASED CONTRAST MEDIA
4.2.1 TECHNICAL OVERVIEW
4.2.2 MARKET DYNAMICS
4.2.3 MARKET ANALYSIS
4.3 IODINATED CONTRAST MEDIA
4.3.1 TECHNICAL OVERVIEW
4.3.2 MARKET DYNAMICS
4.3.3 MARKET ANALYSIS
4.3.4 TYPES – LOW-OSMOLAR AND HIGH-OSMOLAR
4.3.4.1 LOW-OSMOLAR CONTRAST MEDIA (LOCM)
4.3.4.1.1 TECHNICAL OVERVIEW
4.3.4.1.2 MARKET ANALYSIS
4.3.4.2 HIGH-OSMOLAR CONTRAST MEDIA (HOCM)
4.3.4.2.1 TECHNICAL OVERVIEW
4.3.4.2.2 MARKET ANALYSIS
4.4 GADOLINIUM-BASED CONTRAST MEDIA
4.4.1 TECHNICAL OVERVIEW
4.4.2 MARKET DYNAMICS
4.4.3 MARKET ANALYSIS

5 BY ROUTE OF ADMINISTRATION
5.1 INTRODUCTION
5.2 ORAL CONTRAST MEDIA
5.2.1 TECHNICAL OVERVIEW
5.2.2 MARKET DYNAMICS
5.2.3 MARKET ANALYSIS
5.3 INJECTABLE CONTRAST MEDIA
5.3.1 TECHNICAL OVERVIEW
5.3.2 MARKET DYNAMICS
5.3.3 MARKET ANALYSIS
5.3.4 INJECTABLE CONTRAST MEDIA – TYPES
5.3.4.1 INTRAVENOUS (IV)
5.3.4.2 INTRA-ARTERIAL (IA)
5.4 RECTAL CONTRAST MEDIA
5.4.1 TECHNICAL OVERVIEW
5.4.2 MARKET DYNAMICS
5.4.3 MARKET ANALYSIS
5.5 URETHRAL CONTRAST MEDIA
5.5.1 TECHNICAL OVERVIEW
5.5.2 MARKET DYNAMICS
5.5.3 MARKET ANALYSIS

6 BY MEDICAL PROCEDURE
6.1 INTRODUCTION
6.2 X-RAY
6.2.1 TECHNICAL OVERVIEW
6.2.2 MARKET DYNAMICS
6.2.3 MARKET ANALYSIS
6.3 COMPUTED TOMOGRAPHY (CT)
6.3.1 TECHNICAL OVERVIEW
6.3.2 MARKET DYNAMICS
6.3.3 MARKET ANALYSIS
6.4 MAGNETIC RESONANCE IMAGING (MRI)
6.4.1 TECHNICAL OVERVIEW
6.4.2 MARKET DYNAMICS
6.4.3 MARKET ANALYSIS
6.5 ULTRASOUND
6.5.1 TECHNICAL OVERVIEW
6.5.2 MARKET DYNAMICS
6.5.3 MARKET ANALYSIS
6.6 CATHETERIZATION LABORATORY (CATH LAB)
6.6.1 TECHNICAL OVERVIEW
6.6.2 MARKET DYNAMICS
6.6.3 MARKET ANALYSIS

7 BY INDICATION
7.1 INTRODUCTION
7.2 CARDIOVASCULAR DISORDERS
7.2.1 MARKET DYNAMICS
7.2.2 MARKET ANALYSIS
7.3 NEUROLOGICAL DISORDERS
7.3.1 MARKET DYNAMICS
7.3.2 MARKET ANALYSIS
7.4 RESPIRATORY DISEASES
7.4.1 MARKET DYNAMICS
7.4.2 MARKET ANALYSIS
7.5 GASTROINTESTINAL DISORDERS
7.5.1 MARKET DYNAMICS
7.5.2 MARKET ANALYSIS
7.6 ONCOLOGY
7.6.1 MARKET DYNAMICS
7.6.2 MARKET ANALYSIS
7.7 MUSCULOSKELETAL ANOMALIES
7.7.1 MARKET DYNAMICS
7.7.2 MARKET ANALYSIS
7.8 NEPHROLOGICAL DISORDERS
7.8.1 MARKET DYNAMICS
7.8.2 MARKET ANALYSIS

8 BY APPLICATION
8.1 INTRODUCTION
8.2 RADIOLOGY
8.2.1 TECHNICAL OVERVIEW
8.2.2 MARKET DYNAMICS
8.2.3 MARKET ANALYSIS
8.3 INTERVENTIONAL RADIOLOGY
8.3.1 TECHNICAL OVERVIEW
8.3.2 MARKET DYNAMICS
8.3.3 MARKET ANALYSIS
8.4 INTERVENTIONAL CARDIOLOGY
8.4.1 TECHNICAL OVERVIEW
8.4.2 MARKET DYNAMICS
8.4.3 MARKET ANALYSIS

9 GEOGRAPHIC ANALYSIS
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.3 EUROPE
9.4 ASIA-PACIFIC
9.5 REST OF THE WORLD (ROW)

10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 MERGERS & ACQUISITIONS
10.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
10.4 NEW PRODUCT LAUNCH
10.5 EXPANSION
10.6 APPROVALS
10.7 OTHER DEVELOPMENTS

11 COMPANY PROFILES
(OVERVIEW, FINANCIALS, PRODUCTS & SERVICES, STRATEGY, AND DEVELOPMENTS)* Ø SNAPSHOT
11.1 AMAG PHARMACEUTICALS, INC.
11.2 BAYER HEALTHCARE PHARMACEUTICALS
11.3 BRACCO IMAGING SPA (A SUBSIDIARY OF BRACCO S.P.A)
11.4 COVIDIEN
11.5 CMC CONTRAST AB
11.6 DAIICHI SANKYO CO., LTD.
11.7 GE HEALTHCARE
11.8 GENOVIS AB
11.9 GUERBET GROUP
11.10 LANTHEUS MEDICAL IMAGING, INC.
11.11 NANOPET PHARMA GMBH
11.12 NANOSCAN IMAGING, LLC
11.13 SANOCHEMIA PHARMAZEUTIKA AG
11.14 SPAGO IMAGING AB (A SUBSIDIARY OF ACCELERATOR NORDIC AB)
11.15 SUBHRA PHARMA PRIVATE, LTD
11.16 TAEJOON PHARM CO., LTD.
11.17 TARGESON, INC.
11.18 UNIJULES LIFE SCIENCES, LTD.
*DETAILS ON FINANCIALS, PRODUCT & SERVICES, STRATEGY, AND DEVELOPMENTS MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

LIST OF TABLES

TABLE 1 GLOBAL CONTRAST MEDIA MARKET, BY PRODUCT,2010 – 2017 ($MILLION)
TABLE 2 BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 3 CLASSIFICATION OF GBCAS BY U.S. FDA BASED ON NUMBER OF NSF CASES
TABLE 4 MARKET REVENUE, BY PRODUCT,2010 - 2017 ($MILLION)
TABLE 5 MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 6 BARIUM-BASED CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010-2017 ($MILLION)
TABLE 7 IODINATED CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 8 IODINATED MARKET REVENUE, BY TYPE,2010 - 2017 ($MILLION)
TABLE 9 IODINATED-LOCM MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 10 IODINATED-HOCM MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 11 GADOLINIUM-BASED CONTRAST MEDIA MARKET REVENUE,BY GEOGRAPHY, 2010 - 2017 ($MILLION)
TABLE 12 GLOBAL CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION)
TABLE 13 ORAL CONTRAST AGENT MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 14 INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 15 INJECTABLE MARKET REVENUE, BY TYPE,2010 – 2017 ($MILLION)
TABLE 16 INTRAVENOUS INJECTABLE MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 17 INTRA-ARTERIAL INJECTABLE MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 18 RECTAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 19 URETHRAL MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 20 MARKET REVENUE, BY MEDICAL PROCEDURE, 2010 – 2017 ($MILLION)
TABLE 21 X-RAY - MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 22 CT - MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 23 MRI - MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 24 ULTRASOUND - MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 25 CATH LAB MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 26 GLOBAL MARKET, BY INDICATION,2010 – 2017 ($MILLION)
TABLE 27 CARDIOVASCULAR DISEASES - BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 28 NEUROLOGICAL DISORDERS - BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 29 RESPIRATORY DISEASES - MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 30 GASTROINTESTINAL DISORDERS - MARKET,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 31 ONCOLOGY - BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 32 MUSCULOSKELETAL ANOMALIES – BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 33 NEPHROLOGICAL DISORDERS - MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 34 MARKET REVENUE, BY APPLICATION,2010 – 2017 ($MILLION)
TABLE 35 RADIOLOGY CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 36 INTERVENTIONAL RADIOLOGY MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 37 INTERVENTIONAL CARDIOLOGY MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 38 CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 39 NORTH AMERICA: CONTRAST MEDIA MARKET, BY COUNTRY,2010 – 2017 ($MILLION)
TABLE 40 NORTH AMERICA: BY PRODUCT,2010 – 2017 ($MILLION)
TABLE 41 NORTH AMERICA: IODINATED MARKET, BY TYPE, 2010 – 2017 ($MILLION)
TABLE 42 NORTH AMERICA: BY APPLICATION,2010 – 2017 ($MILLION)
TABLE 43 NORTH AMERICA: BY INDICATION,2010 – 2017 ($MILLION)
TABLE 44 NORTH AMERICA: BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION)
TABLE 45 NORTH AMERICA: INJECTABLE CONTRAST MEDIA MARKET,BY TYPE, 2010 – 2017 ($MILLION)
TABLE 46 NORTH AMERICA: BY MEDICAL PROCEDURE, 2010 – 2017 ($MILLION)
TABLE 47 EUROPE: CONTRAST MEDIA MARKET, BY COUNTRY,2010 – 2017 ($MILLION)
TABLE 48 EUROPE: BY PRODUCT,2010 – 2017 ($MILLION)
TABLE 49 EUROPE: IODINATED CONTRAST MEDIA MARKET, BY TYPE,2010 – 2017 ($MILLION)
TABLE 50 EUROPE: BY APPLICATION,2010 – 2017 ($MILLION)
TABLE 51 EUROPE: BY INDICATION,2010 – 2017 ($MILLION)
TABLE 52 EUROPE: BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION)
TABLE 53 EUROPE: INJECTABLE CONTRAST MEDIA MARKET, BY TYPE,2010 – 2017 ($MILLION)
TABLE 54 EUROPE: BY MEDICAL PROCEDURE,2010 – 2017 ($MILLION)
TABLE 55 APAC: CONTRAST MEDIA MARKET, BY COUNTRY,2010 – 2017 ($MILLION)
TABLE 56 APAC: BY PRODUCT,2010 – 2017 ($MILLION)
TABLE 57 APAC: IODINATED CONTRAST MEDIA MARKET, BY TYPE,2010 – 2017 ($MILLION)
TABLE 58 APAC: BY APPLICATION,2010 – 2017 ($MILLION)
TABLE 59 APAC: BY INDICATION,2010 – 2017 ($MILLION)
TABLE 60 APAC: BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION)
TABLE 61 APAC: INJECTABLE CONTRAST MEDIA MARKET, BY TYPE,2010 – 2017 ($MILLION)
TABLE 62 APAC: BY MEDICAL PROCEDURE,2010 – 2017 ($MILLION)
TABLE 63 ROW: REVENUE, BY REGION,2010 – 2017 ($MILLION)
TABLE 64 ROW: MARKET REVENUE, BY PRODUCT,2010 – 2017 ($MILLION)
TABLE 65 ROW: IODINATED CONTRAST MEDIA MARKET, BY TYPE,2010 – 2017 ($MILLION)
TABLE 66 ROW: BY APPLICATION,2010 – 2017 ($MILLION)
TABLE 67 ROW: BY INDICATION,2010 – 2017 ($MILLION)
TABLE 68 ROW: BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION)
TABLE 69 ROW: INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY TYPE,2010 – 2017 ($MILLION)
TABLE 70 ROW: REVENUE, BY MEDICAL PROCEDURE,2010 – 2017 ($MILLION)
TABLE 71 MERGERS & ACQUISITIONS, 2010 – 2012
TABLE 72 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2012
TABLE 73 NEW PRODUCT LAUNCH, 2010 – 2012
TABLE 74 EXPANSION, 2010 – 2012
TABLE 75 APPROVALS, 2010 – 2012
TABLE 76 OTHER DEVELOPMENTS, 2010 – 2012
TABLE 77 AMAG PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES,2009 – 2011 ($MILLION)
TABLE 78 AMAG PHARMACEUTICALS: TOTAL REVENUE, BY SEGMENT,2009 – 2011 ($MILLION)
TABLE 79 AMAG PHARMACEUTICALS: TOTAL PRODUCT SALES, BY PRODUCT, 2009 – 2011 ($MILLION)
TABLE 80 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 81 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE,BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 82 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE,BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 83 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF HEALTHCARE SEGMENT, BY DIVISION, 2009 – 2011 ($MILLION)
TABLE 84 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF HEALTHCARE SEGMENT, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 85 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF CONSUMER HEALTH DIVISION, BY SEGMENT, 2009 - 2011 ($MILLION)
TABLE 86 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF CONSUMER HEALTH DIVISION, BY GEOGRAPHY,2009 – 2011 ($MILLION)
TABLE 87 COVIDIEN: NET SALES AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 88 COVIDIEN: NET SALES, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 89 COVIDIEN: NET SALES, BY PHARMACEUTICAL PRODUCTS,2009 – 2011 ($MILLION)
TABLE 90 COVIDIEN: NET SALES, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 91 DAIICHI SANKYO CO., LTD.: NET SALES AND R&D EXPENSES,2009 – 2011 ($BILLION)
TABLE 92 DAIICHI SANKYO CO., LTD.: NET SALES, BY GEOGRAPHY,2009 – 2011 ($MILLION)
TABLE 93 GENERAL ELECTRIC: TOTAL REVENUE AND R&D EXPENSES,2009 – 2011 ($BILLION)
TABLE 94 GENERAL ELECTRIC: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($BILLION)
TABLE 95 GENERAL ELECTRIC: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($BILLION)
TABLE 96 GENOVIS AB: TOTAL REVENUE AND R&D EXPENSES,2010 – 2012 ($THOU.S.ND)
TABLE 97 GENOVIS AB: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 ($THOU.S.ND)
TABLE 98 GUERBET: TOTAL REVENUE AND R&D EXPENSES,2010 – 2012 ($MILLION)
TABLE 99 GUERBET: TOTAL REVENUE, BY PRODUCTS, 2010 – 2012 ($MILLION)
TABLE 100 GUERBET: TOTAL REVENUE, BY GEOGRAPHY 2010 – 2012 ($MILLION)
TABLE 101 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES,2009 – 2011 ($MILLION)
TABLE 102 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 103 LANTHEUS : TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION)
TABLE 104 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
TABLE 105 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2011 ($MILLION)
TABLE 106 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE,BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 107 ACCELERATOR NORDIC AB: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($THOU.S.ND)

LIST OF FIGURES

FIGURE 1 CONTRAST MEDIA MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
FIGURE 2 CONTRAST MEDIA MARKET SEGMENTATION
FIGURE 3 MARKET DYNAMICS
FIGURE 4 MARKET SHARE ANALYSIS,BY KEY PLAYERS, 2011
FIGURE 5 CONTRAST MEDIA MARKET SEGMENTATION, BY PRODUCT
FIGURE 6 CHEMISTRY OF LOW OSMOLAR CONTRAST MEDIA (LOCM)
FIGURE 7 CHEMISTRY OF HIGH-OSMOLAR CONTRAST MEDIA (HOCM)
FIGURE 8 MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION
FIGURE 9 MARKET SEGMENTATION, BY MEDICAL PROCEDURE
FIGURE 10 MARKET SEGMENTATION, BY INDICATION
FIGURE 11 MARKET SEGMENTATION, BY APPLICATION
FIGURE 12 KEY GROWTH STRATEGIES, 2010 – 2012
FIGURE 13 KEY PLAYERS FOCUSING ON AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES STRATEGY, 2010 – 2012
FIGURE 14 KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCH STRATEGY,2010 – 2012

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[[Updated] 世界の造影剤(コントラスト剤)市場動向(~2017)]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆